The effect of Platelet-rich Plasma and Corticosteroids in treatment of shoulder Tendinitis

Comparative study of Platelet-rich Plasma and Corticosteroids in treatment of Rotator Cuff Tendinopathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

REBEC

Registry ID

RBR-5bt6kd

Enrollment

Unknown

Registered

2017-09-05

Start date

2016-05-31

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator Cuff Impingment Syndrome

Interventions

Experimental group: 26 patients will receive a single subacromial application of platelet rich plasma Control group: 25 patients will receive a single coirticoid subacromial application of betametason

Drug

A12.207.152.693.600

D06.472.040

Eligibility

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: age between 18 and 70 years old; positive Neer test; no previous treatment of IV corticosteroids, injectable or oral in the last 12 months; hemoglobin greater than 11g/dl; platelet count greater than 150000/mm³; and signature of the informed consent form.

Exclusion criteria

Exclusion criteria: association with adhesive capsulitis; complete rupture of the rotator cuff in ultrasonography; loss of follow-up and use of oral or parenteral corticosteroids during the study.

Design outcomes

Primary

Measure	Time frame
Difference between terapeutical responses between the platelet-rich plasma and corticoid groups, observed by comparing results in DASH outcome measure, UCLA Shoulder rating scale and Constant score, through the finding of a probability of significance of less than 5% (p<0,05);Observed: There was no significant difference between the use of corticosteroids and platelet rich plasma in the treatment of rotator cuff syndrome, observed by comparison of DASH Outcome Measure questionnaire (p = 0.20, 0.23 and 0.82 at 1 , 3 and 6 months of treatment respectively), UCLA Shoulder Rating Scale (p=0.83, 0.89 at 1 and 3 months of treatment, p <0.05 at 6 months) and Constant Score (0.50, 0,84,0,22), using as a difference indicator a significance probability of less than 5% (p <0.05).	—

Measure

Time frame

Difference between terapeutical responses between the platelet-rich plasma and corticoid groups, observed by comparing results in DASH outcome measure, UCLA Shoulder rating scale and Constant score, through the finding of a probability of significance of less than 5% (p<0,05);Observed: There was no significant difference between the use of corticosteroids and platelet rich plasma in the treatment of rotator cuff syndrome, observed by comparison of DASH Outcome Measure questionnaire (p = 0.20, 0.23 and 0.82 at 1 , 3 and 6 months of treatment respectively), UCLA Shoulder Rating Scale (p=0.83, 0.89 at 1 and 3 months of treatment, p <0.05 at 6 months) and Constant Score (0.50, 0,84,0,22), using as a difference indicator a significance probability of less than 5% (p <0.05).

—

Secondary

Measure	Time frame
No secondary outcomes were studied in this study	—

Countries

Brazil

Contacts

Public ContactArthur Azevedo

Universidade Tiradentes

rangel.aaz@gmail.com+55(79)99934-8300

Outcome results

None listed

Source: REBEC (via WHO ICTRP)